Generic Name and Formulations:
Rasagiline 0.5mg, 1mg; tabs.
Indications for AZILECT:
Parkinson's disease (PD).
Monotherapy or adjunct without levodopa: 1mg once daily. Concomitant levodopa with/without other PD drugs (eg, dopamine agonist, amantadine, anticholinergics): initially 0.5mg once daily; may increase to 1mg once daily (consider reducing levodopa dose based on response). Mild hepatic impairment (Child-Pugh score 5–6) or concomitant CYP1A2 inhibitors: 0.5mg once daily.
During or within 2 weeks of meperidine, tramadol, methadone, propoxyphene, MAOIs including other selective MAO-B inhibitors. Concomitant dextromethorphan, St. John's wort, cyclobenzaprine.
Monitor for new onset hypertension or hypertension that is not adequately controlled after starting therapy. Avoid tyramine-rich foods (see full labeling). Monitor for drowsiness or sleepiness. Mild hepatic impairment: reduce dose; moderate to severe hepatic impairment (Child-Pugh score ≥7): not recommended. Monitor for hallucinations, psychotic or compulsive behaviors; consider reduce dose or discontinue if develops. Monitor for melanoma. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Possible hypertensive crisis with excess dietary tyramine (see full labeling). Potentiated by CYP1A2 inhibitors (eg, ciprofloxacin). Concomitant antidepressants (eg, SSRIs, SNRIs, triazolopyridines, tricyclics, tetracyclics): not recommended; increased risk of serotonin syndrome. Allow at least 14 days after discontinuing rasagiline before starting SSRIs, SNRIs, triazolpyridines, tricyclics, tetracyclics; allow 5 weeks after discontinuing fluoxetine before starting rasagiline. Caution with sympathomimetics (eg, nasal, oral, ophthalmic decongestants or cold remedies).
As monotherapy: flu syndrome, arthralgia, depression, dyspepsia. With levodopa: also dyskinesia, accidental injury, weight loss, postural hypotension, GI upset, anorexia, abdominal pain, constipation, dry mouth, rash, abnormal dreams, fall.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
- Direct-to-Consumer Genetic Test for Select BRCA Mutations Gets FDA Nod
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|